TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9380609
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g of piracetam combined with cognitive therapy
Study: 9380609
Drug: 4.8 g
Normalized name: ALCOHOL 74.8 g in 100 g TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g of piracetam combined with cognitive therapy
Study: 29742587
Drug: Probenecid (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (25 mg/kg) and N-acetylcysteine (140 mg/kg)
Study: 19549743
Drug: GHR antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GHR antagonist (pegvisomant, 10 mg/d)
Study: 14984181
Drug: Ozonated autohemotherapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated autohemotherapy (50 microg/ml)
Study: 28760246
Drug: FDC 0.4/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC 0.4/5 mg
Study: 28760246
Drug: FDC 0.2/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC 0.2/5 mg
Study: 26018348
Drug: CNI-free de
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-free de novo immunosuppressive treatment (mycofenolate mofetil, steroids, basiliximab) with delayed introduction of sirolimus
Study: 19031934
Drug: Severe (grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe (grade 3 or 4) hematological toxicity during chemotherapy
Study: 19031934
Drug: No severe
Approvals — FDA: no, EMA: no, PMDA: no
Description: No severe myelotoxicity during chemotherapy
Study: 10634823
Drug: alpha-tocopherol supplementation
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol supplementation (50 mg daily)
Study: 10634823
Drug: beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene supplementation (20 mg daily)
Study: 8430681
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg twice a day)
Study: 29178491
Drug: Etrolizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab (0.3 to 10 mg/kg, administered intravenously or subcutaneously)
Study: 19032127
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination treatments (budesonide/formoterol and salmeterol/fluticasone with terbutaline as needed)
Study: 8737097
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose warfarin and aspirin
Study: 8466726
Drug: Isradipine plus
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine plus spirapril 3 mg
Study: 8466726
Drug: Isradipine plus
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine plus pindolol 5 mg
Study: 8466726
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with isradipine
Study: 8466726
Drug: Side-effects related
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side-effects related to treatment
Study: 22742205
Drug: IV montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV montelukast 7 mg
Study: 22742205
Drug: IV montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV montelukast 14 mg
Study: 22742205
Drug: IV montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV montelukast 7 mg and 14 mg
Study: 20299485
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg NCX 4016 b.i.d.
Study: 20299485
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NCX 4016 and aspirin
Study: 18853112
Drug: Langchuang No.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Langchuang No.1 or 2 (Chinese recipes) in addition to Western medicine
Study: 16422913
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg, flexible-dose regimen (5 mg or 20 mg possible after 4 weeks)
Study: 1997509
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (3.2 mg/day)
Study: 1997509
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (0.8 mg/day)
Study: 1997509
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (40 mg/day)
Study: 1997509
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (10 mg/day)
Study: 1997509
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisolone (40 mg/day)
Study: 1997509
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisolone (10 mg/day)
Study: 6426828
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (DPA) 400 mg
Study: 31092654
Drug: Medical grade
Normalized name: Skarcade Medical Grade Silicone Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical grade kanuka honey (90%)/glycerine (10%) cream
Study: 29408453
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg RAPA daily
Study: 20133153
Drug: Four SES
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four SES risk factors (low monthly income, less than a college education, unmarried, unemployed)
Study: 12205255
Drug: SIMV+VG 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMV+VG 4.5 (V(T mech) set at 4.5 mL/kg)
Study: 12205255
Drug: SIMV+VG 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMV+VG 3.0 (V(T mech) set at 3.0 mL/kg)
Study: 7723681
Drug: Nibbling diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nibbling diet (17 meals daily)
Study: 7723681
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (3 meals daily)
Study: 6352383
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg orally once weekly)
Study: 28550255
Drug: Sembragiline 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sembragiline 1 mg
Study: 28550255
Drug: Sembragiline 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sembragiline 5 mg
Study: 23383224
Drug: Amoxicillin/clavulanate potassium
Normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate potassium (A/CP)
Study: 19769010
Drug: Skipping medications
Normalized name: piperonyl butoxide / pyrethrins Medicated Shampoo [Stop Lice Maximum Strength]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skipping medications
Study: 17680222
Drug: Pulsed-dose-rate (PDR)
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed-dose-rate (PDR) brachytherapy, prescribed reference dose of 49.8 Gy in 83 fractions of 0.6 Gy every hour, total treatment time 3-4 days.
Study: 17680222
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) brachytherapy, prescribed reference dose of 32 Gy in eight fractions of 4 Gy, twice daily.
Study: 15197804
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 8/4 mg
Study: 11224833
Drug: MnCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnCC vaccine (4 doses at 2, 4, 6 months)
Study: 11224833
Drug: MnCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnCC vaccine (after Dose 3)
Study: 11224833
Drug: MnCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnCC vaccine (after Dose 4)
Study: 11224833
Drug: MnCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnCC vaccine (after three doses)
Study: 11224833
Drug: MnCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnCC vaccine (after booster)
Study: 11224833
Drug: 7-valent conjugate
Normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugate pneumococcal vaccine (control)
Study: 7994879
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot (3.6 mg) administered monthly for 6 months (n = 22)
Study: 7994879
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot (3.6 mg) administered monthly for 12 months (n = 8)
Study: 7994879
Drug: Goserelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin depot (3.6 mg) administered for 3 months
Study: 973959
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg t.d.s. for 5 days)
Study: 30423641
Drug: Wallis implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wallis implant after lumbar discectomy
Study: 21500885
Drug: Cognitive-behavioral analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral analysis system of psychotherapy (CBASP) plus pharmacotherapy
Study: 21500885
Drug: Brief supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief supportive psychotherapy (BSP) plus pharmacotherapy
Study: 19062268
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (toremifene or tamoxifen)
Study: 19062268
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy (CMF or AC plus toremifene or tamoxifen)
Study: 17409581
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for heart failure
Study: 11464037
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg apomorphine SL
Study: 11464037
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg apomorphine SL
Study: 8089245
Drug: Chlorhexidine (0.12%)
Normalized name: chlorhexidine 12 MG
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (0.12%) rinses, 15 ml, 2 times daily for 1 month
Study: 8089245
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution rinses
Study: 3385044
Drug: Indomethacin therapy
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin therapy (double-blind, controlled, crossover trial in 14 patients)
Study: 18390799
Drug: Higher-dose oral
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose oral contraceptive pill (OCP) (35 microg ethinyl estradiol/2 mg cyproterone acetate)
Study: 7577204
Drug: High-dose cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide, cisplatin, and carmustine with autologous bone marrow support
Study: 7577204
Drug: Low-dose cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose cyclophosphamide, cisplatin, and carmustine
Study: 1663851
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for back pain
Study: 28421317
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement (ONS) - 250 ml of Arginaid Water ingested in the evening before the experiment and at 7:00 am on the day of the experiment.
Study: 28421317
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement (ONS) - 250 ml of Arginaid Water.
Study: 21219660
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 80 mcg and albuterol 400 mcg
Study: 19395131
Drug: Isohumulones 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isohumulones 32 mg
Study: 19395131
Drug: Isohumulones 48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isohumulones 48 mg
Study: 19395131
Drug: Isohumulones 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isohumulones 16 mg
Study: 17948074
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2 g on the night before surgery and 1 g twice daily for 5 days after surgery)
Study: 12202015
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg qd plus sertraline 50 mg qd
Study: 12202015
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg qd with placebo
Study: 10414911
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg/day)
Study: 9818688
Drug: Both G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both G-CSF and GM-CSF
Study: 8580921
Drug: Topical retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid (n = 32)
Study: 30939922
Drug: Automated hovering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated hovering intervention with patient-level incentives for daily weight monitoring and diuretic adherence, combined with automated feedback into the clinical care pathway.
Study: 27817819
Drug: FF 100
Normalized name: APAP 325/CAFF 100/ISOMETHEPTENE 65MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 100 μg OD
Study: 27817819
Drug: FP 100
Normalized name: Peanut Allergen-dnfp 100 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 100 μg BD
Study: 27817819
Drug: FP 250
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 250 μg BD
Study: 27817819
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 μg OD
Study: 24809261
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking agents (NMBA) - vecuronium, loading dose of 0.1 mg/kg, continuous infusion of 0.05 mg/kg/h for 24-48 hours
Study: 24809261
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NMBA treatment)
Study: 19318295
Drug: Diclofenac epolamine
Normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac epolamine patch
Study: 17311621
Drug: Viusid (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viusid (three sachets daily) + IFN alpha‐2b (5 MU on alternate days) + ribavirin (13 mg/kg daily)
Study: 17311621
Drug: IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2b (5 MU on alternate days) + ribavirin (13 mg/kg daily)
Study: 17311621
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (without Viusid)
Study: 15500398
Drug: Oxypurinol added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxypurinol added to standard therapy
Study: 11174617
Drug: Early indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early indomethacin treatment (3 x 0.2 mg/kg every 12 hours, starting on day 3)
Study: 11174617
Drug: Early indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early indomethacin treatment
Study: 11174617
Drug: Late indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late indomethacin treatment (starting on day 7)
Study: 3387686
Drug: Dipyridamole 100
Normalized name: dipyridamole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 100 mg and acetylcysteine 100 mg every 6 h
Study: 3387686
Drug: Acetylcysteine 100
Normalized name: acetylcysteine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 100 mg every 6 h
Study: 28150367
Drug: 2.5% benzoyl
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% benzoyl peroxide gel
Study: 2143890
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) chemotherapy
Study: 2143890
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration
Study: 7285484
Drug: d-amphetamine 25
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 25 mg
Study: 7285484
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg d-amphetamine)
Study: 25351237
Drug: 0.5 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µg/kg DEX in 10 mL isotonic saline (group II)
Study: 25351237
Drug: 1.0 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 µg/kg DEX in 10 mL isotonic saline (group III)
Study: 25351237
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL isotonic saline (group I)
Study: 17021811
Drug: Continued thiamazole
Normalized name: thiamazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued thiamazole medication (11.0+/‐7.0 mg/day)
Study: 17021811
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of thiamazole for 2 days
Study: 17021811
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of thiamazole for 1 day
Study: 9780135
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine administration
Study: 9780135
Drug: Smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cocaine administration
Study: 7825033
Drug: PBMC co-cultivated
Normalized name: Cultivated mushroom
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMC co-cultivated with phytohemagglutinin‐P activated PBMC from healthy, HIV‐1 antibody negative donors
Study: 29288250
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (250,000 or 500,000 IU)
Study: 25531677
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral glucose-lowering drugs excluding TZD)
Study: 21327593
Drug: Repeated pulse
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated pulse therapy of methylprednisolone (1 g for 3 days) and cyclophosphamide (15 mg/kg per day for 2 days), followed by dexamethasone (5 mg every 6 hours) until PaO2 >80 mmHg or repeated 1 g MP for 3 days and 1 g CP for 1 day if PaO2 <60 mmHg
Study: 21327593
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of cyclophosphamide (2 mg/kg per day) and dexamethasone (5 mg every 6 hours) for 14 days
Study: 18685945
Drug: Landiolol 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.01 mg x kg(‐1) x min(‐1)
Study: 18685945
Drug: Landiolol 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.02 mg x kg(‐1) x min(‐1)
Study: 18685945
Drug: Landiolol 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.03 mg x kg(‐1) x min(‐1)
Study: 18685945
Drug: Landiolol 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.04 mg x kg(‐1) x min(‐1)
Study: 16573799
Drug: Lactulose (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (single dose)
Study: 16573799
Drug: Lactulose (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (long-term administration)
Study: 15339557
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial chemoembolization (TACE) and traditional Chinese medicine (TCM)
Study: 10712318
Drug: Quinupristin/dalfopristin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinupristin/dalfopristin (7.5 mg/kg every 8 h)
Study: 3895289
Drug: Iopamidol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (250 mg I/ml)
Study: 3895289
Drug: Ioxithalamate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxithalamate (250 mg I/ml)
Study: 22379745
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg thrice daily plus omeprazole 20 mg twice daily
Study: 18502357
Drug: alpha‐tocopherol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐tocopherol 300 mg orally 5 to 6 hours before surgery
Study: 16005690
Drug: Clobazam (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (10mg oral dose)
Study: 10362210
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement (0.625 mg/day conjugated equine estrogens and 2.5 mg/day medroxyprogesterone acetate)
Study: 10362210
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement plus lovastatin
Study: 8964637
Drug: Kd 2
Normalized name: POLYQUATERNIUM-7 (70/30 ACRYLAMIDE/DADMAC; 1600 KD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kd 2 mEq/l (standard potassium removal)
Study: 2167702
Drug: VAC (vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2)
Study: 2167702
Drug: VACE (vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACE (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, etoposide 80 mg/m2 for 3 days)
Study: 31182351
Drug: Nabilone (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (target 1–2 mg)